Skip to main content
SpringerLink
Log in

The Role of Radiology in Personalized Medicine

  • Chapter
  • First Online:
Personalized Medicine

Part of the book series: Europeanization and Globalization ((EAG,volume 2))

Abstract

Radiological diagnostics in personalized medicine provides indispensable morphological and functional information, unique for every individual. Volumetric imaging enables follow-up of suspicious nodules detected with screening or incidentally obtained on radiological imaging and assessment of tumor response to treatment. Assessment of neovascularity with perfusion-based imaging and restriction of water motion with diffusion-weighted MRI offers better distinction between benign and malignant lesions. Functional MRI of the brain delineates eloquent cortical areas and diffusion tensor imaging allows for in vivo assessment of white matter tracts characteristic for individual patients as prerequisites for guiding invasive procedures. Imaging biomarkers are crucial in personalized diagnostics and therapy. Prognostic biomarkers may prevent aggressive treatment in patients with indolent or slowly progressive disease. Imaging is mandatory for the assessment of therapeutic response and discrimination of responders and non-responders in the early phase of treatment. Identifying biomarkers before clinical manifestation followed by therapeutic intervention prevents the development of a disease. Our ability to detect smaller lesions using sophisticated technology increases the necessity to characterize such findings by extension of diagnostics. Incidental findings of preclinical disorders or indolent lesions without potential to disturb subject’s health increase the risk of overdiagnosis. Imaging provides detailed information for the assessment of tumor resectability and is used to guide invasive procedures, including interventional radiology. Different imaging modalities can be used to guide biopsy needle to the specific part of the tumor with higher concentration of biomarkers. These sophisticated procedures are tailored to the individual patient’s illness which is essential in personalized diagnostics and treatment.

Professor Damir Miletić, M.D., Ph.D., Head of the Department of Radiology, KBC Rijeka, Rijeka, Croatia.

 Petra Valković Zujić, M.D., Ph.D., Clinical Radiology, Department of Radiology, KBC Rijeka.

 Ronald Antulov, M.D., Ph.D., Clinical Radiology, Department of Radiology, KBC Rijeka, Krešimirova 42, Rijeka, Croatia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    Evans and Johnson (2001), Hoehe et al. (2003), and Terra and Johnson (2002).

  2. 2.

    Kelkar and Reineke (2011).

  3. 3.

    Citri and Yarden (2006).

  4. 4.

    Vogel et al. (2002).

  5. 5.

    Santinelli et al. (2008) and Krawczyk et al. (2009).

  6. 6.

    Vanden Bempt et al. (2007).

  7. 7.

    European Society of Radiology (2011).

  8. 8.

    European Society of Radiology (2011).

  9. 9.

    Thrall (2004).

  10. 10.

    Thrall (2004).

  11. 11.

    Nevins et al. (2003).

  12. 12.

    European Society of Radiology (2011).

  13. 13.

    Thrall (2004).

  14. 14.

    Nevins et al. (2003).

  15. 15.

    Crommelin et al. (2011).

  16. 16.

    Crommelin et al. (2011).

  17. 17.

    Thrall (2004).

  18. 18.

    Basu (2010).

  19. 19.

    Crommelin et al. (2011).

  20. 20.

    Kostakoglu et al. (2002).

  21. 21.

    Bombardieri (2006).

  22. 22.

    Klayton et al. (2012).

  23. 23.

    Klayton et al. (2012).

  24. 24.

    Eisenhauer et al. (2009).

  25. 25.

    Mozley et al. (2010).

  26. 26.

    Buckler et al. (2010).

  27. 27.

    Van Klaveren et al. (2009).

  28. 28.

    Atreya et al. (2014).

  29. 29.

    Nordsmark et al. (2005).

  30. 30.

    Thrall (2004).

  31. 31.

    Schoder et al. (2009).

  32. 32.

    Welch and Black (2010).

  33. 33.

    Bessho (1996a).

  34. 34.

    European Society of Radiology (2011) and Schoder et al. (2009).

  35. 35.

    Bessho (1996b).

  36. 36.

    Rumboldt et al. (2005).

  37. 37.

    Srinivasan et al. (2012).

  38. 38.

    Lacerda and Law (2009).

  39. 39.

    Ludemann et al. (2009) and Vandecaveye et al. (2007).

  40. 40.

    Crommelin et al. (2011).

  41. 41.

    Abdel Razek et al. (2007).

  42. 42.

    Abdel Razek et al. (2007).

  43. 43.

    Hricak (2011).

  44. 44.

    Hricak et al. (2004).

  45. 45.

    Burgel et al. (2006).

  46. 46.

    Nicolaidis (2013).

  47. 47.

    Brodbelt (2011).

  48. 48.

    Pillai (2010).

  49. 49.

    Jellison et al. (2004).

  50. 50.

    Abdel Razek et al. (2007).

  51. 51.

    Smits et al. (2007).

References

  • Abdel Razek AA, Kandeel AY, Soliman N, El-shenshawy HM, Kamel Y, Nada N, Denewar A (2007) Role of diffusion-weighted echo-planar MR imaging in differentiation of residual or recurrent head and neck tumors and posttreatment changes. AJNR Am J Neuroradiol 28(6):1146–1152. doi:10.3174/ajnr.A0491

    Article  Google Scholar 

  • Atreya R, Neumann H, Neufert C, Waldner MJ, Billmeier U, Zopf Y, Willma M, App C, Munster T, Kessler H, Maas S, Gebhardt B, Heimke-Brinck R, Reuter E, Dorje F, Rau TT, Uter W, Wang TD, Kiesslich R, Vieth M, Hannappel E, Neurath MF (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 20(3):313–318. doi:10.1038/nm.3462

    Article  Google Scholar 

  • Basu S (2010) Personalized versus evidence-based medicine with PET-based imaging. Nat Rev Clin Oncol 7(11):665–668. doi:10.1038/nrclinonc.2010.121

    Article  Google Scholar 

  • Bessho F (1996a) Effects of mass screening on age-specific incidence of neuroblastoma. Int J Cancer 67(4):520–522. doi:10.1002/(SICI)1097-0215(19960807)67:4<520::AID-IJC10>3.0.CO;2-B

    Article  Google Scholar 

  • Bessho F (1996b) Where should neuroblastoma mass screening go? Lancet 348(9043):1672. doi:10.1016/S0140-6736(05)65814-X

    Article  Google Scholar 

  • Bombardieri E (2006) The added value of metabolic imaging with FDG-PET in oesophageal cancer: prognostic role and prediction of response to treatment. Eur J Nucl Med Mol Imaging 33(7):753–758. doi:10.1007/s00259-006-0147-x

    Article  Google Scholar 

  • Brodbelt A (2011) Clinical applications of imaging biomarkers. Part 2. The neurosurgeon’s perspective. Br J Radiol 84(Spec No 2):S205–208. doi:10.1259/bjr/19282704

    Google Scholar 

  • Buckler AJ, Mozley PD, Schwartz L, Petrick N, McNitt-Gray M, Fenimore C, O’Donnell K, Hayes W, Kim HJ, Clarke L, Sullivan D (2010) Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. Acad Radiol 17(1):107–115. doi:10.1016/j.acra.2009.06.019

    Article  Google Scholar 

  • Burgel U, Amunts K, Hoemke L, Mohlberg H, Gilsbach JM, Zilles K (2006) White matter fiber tracts of the human brain: three-dimensional mapping at microscopic resolution, topography and intersubject variability. Neuroimage 29(4):1092–1105. doi:10.1016/j.neuroimage.2005.08.040

    Article  Google Scholar 

  • Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–516. doi:10.1038/nrm1962

    Article  Google Scholar 

  • Crommelin DJ, Storm G, Luijten P (2011) ‘Personalised medicine’ through ‘personalised medicines’: time to integrate advanced, non-invasive imaging approaches and smart drug delivery systems. Int J Pharm 415(1-2):5–8. doi:10.1016/j.ijpharm.2011.02.010

    Article  Google Scholar 

  • Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. doi:10.1016/j.ejca.2008.10.026

    Article  Google Scholar 

  • European Society of Radiology (2011) Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging 2(6):621–630. doi:10.1007/s13244-011-0125-0

    Article  Google Scholar 

  • Evans WE, Johnson JA (2001) Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9–39. doi:10.1146/annurev.genom.2.1.9

    Article  Google Scholar 

  • Hoehe MR, Timmermann B, Lehrach H (2003) Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr Pharm Biotechnol 4(6):351–378

    Article  Google Scholar 

  • Hricak H (2011) Oncologic imaging: a guiding hand of personalized cancer care. Radiology 259(3):633–640. doi:10.1148/radiol.11110252

    Article  Google Scholar 

  • Hricak H, Wang L, Wei DC, Coakley FV, Akin O, Reuter VE, Gonen M, Kattan MW, Onyebuchi CN, Scardino PT (2004) The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 100(12):2655–2663. doi:10.1002/cncr.20319

    Article  Google Scholar 

  • Jellison BJ, Field AS, Medow J, Lazar M, Salamat MS, Alexander AL (2004) Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am J Neuroradiol 25(3):356–369

    Google Scholar 

  • Kelkar SS, Reineke TM (2011) Theranostics: combining imaging and therapy. Bioconjug Chem 22(10):1879–1903. doi:10.1021/bc200151q

    Article  Google Scholar 

  • Klayton T, Li T, Yu JQ, Keller L, Cheng J, Cohen SJ, Meropol NJ, Scott W, Xu-Welliver M, Konski A (2012) The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinoma. J Gastrointest Cancer 43(4):612–618. doi:10.1007/s12029-012-9412-3

    Article  Google Scholar 

  • Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43(8):1018–1027

    Google Scholar 

  • Krawczyk N, Banys M, Neubauer H, Solomayer EF, Gall C, Hahn M, Becker S, Bachmann R, Wallwiener D, Fehm T (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 29(10):4019–4024

    Google Scholar 

  • Lacerda S, Law M (2009) Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 19(4):527–557. doi:10.1016/j.nic.2009.08.007

    Article  Google Scholar 

  • Ludemann L, Warmuth C, Plotkin M, Forschler A, Gutberlet M, Wust P, Amthauer H (2009) Brain tumor perfusion: comparison of dynamic contrast enhanced magnetic resonance imaging using T1, T2, and T2* contrast, pulsed arterial spin labeling, and H2(15)O positron emission tomography. Eur J Radiol 70(3):465–474. doi:10.1016/j.ejrad.2008.02.012

    Article  Google Scholar 

  • Mozley PD, Schwartz LH, Bendtsen C, Zhao B, Petrick N, Buckler AJ (2010) Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. Ann Oncol 21(9):1751–1755. doi:10.1093/annonc/mdq051

    Article  Google Scholar 

  • Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M (2003) Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 12 Spec No 2:R153–R157. doi:10.1093/hmg/ddg287

    Google Scholar 

  • Nicolaidis S (2013) Personalized medicine in neurosurgery. Metabolism 62(Suppl 1):S45–S48. doi:10.1016/j.metabol.2012.08.022

    Article  Google Scholar 

  • Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A, Adam M, Molls M, Dunst J, Terris DJ, Overgaard J (2005) Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 77(1):18–24. doi:10.1016/j.radonc.2005.06.038

    Article  Google Scholar 

  • Pillai JJ (2010) The evolution of clinical functional imaging during the past 2 decades and its current impact on neurosurgical planning. AJNR Am J Neuroradiol 31(2):219–225. doi:10.3174/ajnr.A1845

    Article  Google Scholar 

  • Rumboldt Z, Al-Okaili R, Deveikis JP (2005) Perfusion CT for head and neck tumors: pilot study. AJNR Am J Neuroradiol 26(5):1178–1185

    Google Scholar 

  • Santinelli A, Pisa E, Stramazzotti D, Fabris G (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Int J Cancer 122(5):999–1004. doi:10.1002/ijc.23051

    Article  Google Scholar 

  • Schoder H, Fury M, Lee N, Kraus D (2009) PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med 50(Suppl 1):74S–88S. doi:10.2967/jnumed.108.057208

    Google Scholar 

  • Smits M, Vernooij MW, Wielopolski PA, Vincent AJ, Houston GC, van der Lugt A (2007) Incorporating functional MR imaging into diffusion tensor tractography in the preoperative assessment of the corticospinal tract in patients with brain tumors. AJNR Am J Neuroradiol 28(7):1354–1361. doi:10.3174/ajnr.A0538

    Article  Google Scholar 

  • Srinivasan A, Mohan S, Mukherji SK (2012) Biologic imaging of head and neck cancer: the present and the future. AJNR Am J Neuroradiol 33(4):586–594. doi:10.3174/ajnr.A2535

    Article  Google Scholar 

  • Terra SG, Johnson JA (2002) Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward. Am J Cardiovasc Drugs 2(5):287–296

    Article  Google Scholar 

  • Thrall JH (2004) Personalized medicine. Radiology 231(3):613–616. doi:10.1148/radiol.2313040323

    Article  Google Scholar 

  • Van Klaveren RJ, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, van Iersel CA, van den Bergh KA, van ‘t Westeinde S, van der Aalst C, Thunnissen E, Xu DM, Wang Y, Zhao Y, Gietema HA, de Hoop BJ, Groen HJ, de Bock GH, van Ooijen P, Weenink C, Verschakelen J, Lammers JW, Timens W, Willebrand D, Vink A, Mali W, de Koning HJ (2009) Management of lung nodules detected by volume CT scanning. N Engl J Med 361(23):2221–2229. doi:10.1056/NEJMoa0906085

    Google Scholar 

  • Vandecaveye V, De Keyzer F, Nuyts S, Deraedt K, Dirix P, Hamaekers P, Vander Poorten V, Delaere P, Hermans R (2007) Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 67(4):960–971. doi:10.1016/j.ijrobp.2006.09.020

    Article  Google Scholar 

  • Vanden Bempt I, Drijkoningen M, De Wolf-Peeters C (2007) The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Curr Opin Oncol 19(6):552–557. doi:10.1097/CCO.0b013e3282f0ad8e

    Article  Google Scholar 

  • Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20(3):719–726

    Article  Google Scholar 

  • Welch HG, Black WC (2010) Overdiagnosis in cancer. J Natl Cancer Inst 102(9):605–613. doi:10.1093/jnci/djq099

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, KBC Rijeka, Rijeka, Croatia

    D. Miletić M.D., Ph.D., P. Valković-Zujić M.D., Ph.D. & R. Antulov M.D., Ph.D.

Authors
  1. D. Miletić M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Valković-Zujić M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Antulov M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Miletić M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Jean Monnet Department of European Public Law, University of Rijeka, Rijeka, Croatia

    Nada Bodiroga-Vukobrat

  2. Croatian Academy of Sciences and Arts, Rijeka, Croatia

    Daniel Rukavina

  3. Department of Biotechnology, University of Rijeka , Rijeka, Croatia

    Krešimir Pavelić

  4. University of Applied Sciences, Hochschule für öffentliche Verwaltung und Finanzen Ludwigsburg, Ludwigsburg, Germany

    Gerald G. Sander

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Miletić, D., Valković-Zujić, P., Antulov, R. (2016). The Role of Radiology in Personalized Medicine. In: Bodiroga-Vukobrat, N., Rukavina, D., Pavelić, K., Sander, G. (eds) Personalized Medicine. Europeanization and Globalization, vol 2. Springer, Cham. https://doi.org/10.1007/978-3-319-39349-0_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-39349-0_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-39347-6

  • Online ISBN: 978-3-319-39349-0

  • eBook Packages: Law and CriminologyLaw and Criminology (R0)

Publish with us

Policies and ethics

Search

Navigation